Optimizing Piperacillin Dosing in Pediatric Liver Transplant Recipients: A Case Series
Authors:
- Ronaldo Morales JuniorRJRonaldo Morales Junior
- Anhar HosawiAHAnhar Hosawi
- Sonya Tang GirdwoodSGSonya Tang Girdwood
- Min DongMDMin Dong
- Vanessa D’ Amaro JuodinisVJVanessa D’ Amaro Juodinis
- Paschoalina RomanoPRPaschoalina Romano
- Pérsio de Almeida Rezende EbnerPEPérsio de Almeida Rezende Ebner
- Nilo José Coelho DuarteNDNilo José Coelho Duarte
- Daniela Carla de SouzaDSDaniela Carla de Souza
- Silvia Regina Cavani Jorge SantosSSSilvia Regina Cavani Jorge Santos
- 25 September 2024
- journal article
- research article
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (7) , e14860
Abstract
Background: Pathophysiological changes post‐liver transplantation impact the pharmacokinetics and pharmacodynamics of antibiotics. Piperacillin, often used in combination with tazobactam, is a key antibiotic after transplantation to its broad‐spectrum activity, but there is a lack of specific pharmacokinetic data in this population. This study aims to describe the pharmacokinetic parameters and target attainment of piperacillin in pediatric liver transplant recipients.Methods: Patients with preserved renal function (estimated glomerular filtration rate > 50 mL/min/1.73 m2) receiving intravenous piperacillin‐tazobactam at 112.5 mg/kg every 8 h (100 mg piperacillin/12.5 mg tazobactam), with a rapid infusion (0.5–1 h), were included. Two blood samples per child were collected during the same interval within 48 h of starting therapy. A Bayesian approach was applied to estimate individual pharmacokinetic parameters and perform dosing recommendations against Enterococcus spp., Enterobacterales and Pseudomonas aeruginosa.Results: Eight patients with median age of 8 months were included. Median piperacillin clearance and central volume of distribution for the cohort were 11.11 L/h/70 kg and 9.80 L/70 kg, respectively. Seven patients (87.5%) presented with concentrations below the target of 100% fT > MIC. Simulations suggested that these patients required more frequent dosing and extended duration of infusion to ensure target attainment. One patient (12.5%) had trough concentrations that exceed 16 mg/L and could receive a lower daily dose.Conclusions: This case series highlights the importance of personalized therapy in pediatric liver transplant recipients due to the unpredictable and highly variable piperacillin pharmacokinetics in this population.Keywords
Funding Information
- National Institute of General Medical Sciences (R35GM14670)
This publication has 17 references indexed in Scilit:
- Pharmacokinetic and pharmacodynamic considerations of antibiotics and antifungals in liver transplantation recipientsLiver Transplantation, 2022
- Extended infusion improves meropenem and piperacillin/tazobactam effectiveness in septic burn patients with normal renal by applying pharmacokinetics-pharmacodynamics approachInternational Journal of Antimicrobial Agents, 2021
- From Therapeutic Drug Monitoring to Model‐Informed Precision Dosing for AntibioticsClinical Pharmacology & Therapeutics, 2021
- A guide to therapeutic drug monitoring of β‐lactam antibioticsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2021
- Early mortality after liver transplantation: Defining the course and the causeSurgery, 2018
- Model-based precision dosing of sirolimus in pediatric patients with vascular anomaliesEuropean Journal of Pharmaceutical Sciences, 2017
- Dose optimization of piperacillin/tazobactam in critically ill childrenJournal of Antimicrobial Chemotherapy, 2017
- GFR Estimating Equations and Liver DiseaseAdvances in Chronic Kidney Disease, 2015
- Population Pharmacokinetics of Piperacillin/Tazobactam in Critically Ill Young ChildrenThe Pediatric Infectious Disease Journal, 2014
- The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactamJournal of Antimicrobial Chemotherapy, 1993